Mylan Laboratories Ltd. - Research Center
524794 MATRIXLAB Group (B) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 09 | Mar ' 08 | Mar ' 07 | Mar ' 06 | Mar ' 05 | |
|---|---|---|---|---|---|
| Sales | 1,502.14 | 978.76 | 749.51 | 667.14 | 641.32 |
| Operating profit | 327.62 | -223.25 | 97.51 | 83.65 | 178.18 |
| Interest | 56.92 | 27.27 | 15.40 | 8.15 | 6.28 |
| Gross profit | 292.55 | -230.34 | 132.59 | 234.06 | 182.81 |
| EPS (Rs) | 12.22 | -19.30 | 6.46 | 11.87 | 8.81 |
Annual
results in details
| Mar ' 09 | Mar ' 08 | Mar ' 07 | Mar ' 06 | Mar ' 05 | |
|---|---|---|---|---|---|
| Other income | 21.85 | 20.18 | 50.48 | 158.57 | 10.91 |
| Stock adjustment | -66.63 | -72.58 | -2.82 | -16.78 | -11.61 |
| Raw material | 748.00 | 534.12 | 387.54 | 402.98 | 325.87 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 97.01 | 70.38 | 59.84 | 48.00 | 35.96 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | 177.65 | 106.41 | 80.09 | 31.12 | 15.93 |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 218.49 | 563.68 | 127.35 | 118.17 | 97.00 |
| Provisions made | - | - | - | - | - |
| Depreciation | 35.58 | 29.54 | 25.07 | 22.34 | 19.13 |
| Taxation | 68.02 | 38.48 | 7.90 | 29.34 | 31.71 |
| Net profit / loss | 188.95 | -298.36 | 99.61 | 182.38 | 131.97 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 30.92 | 30.92 | 30.82 | 30.73 | 29.95 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | 369.11 | 368.77 | 364.06 | 687.51 | 499.07 |
| Agg.of non promotoholding (%) | 23.87 | 23.85 | 23.62 | 44.75 | 33.34 |
| OPM (%) | 21.81 | -22.81 | 13.01 | 12.54 | 27.78 |
| GPM (%) | 19.20 | -23.06 | 16.57 | 28.35 | 28.03 |
| NPM (%) | 12.40 | -29.87 | 12.45 | 22.09 | 20.23 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis